Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Alnylam Pharmaceuticals, Inc. - Common Stock (NQ:ALNY)

445.79 -14.97 (-3.25%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Alnylam Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
20 21 Next >
News headline image
Beyond The Numbers: 28 Analysts Discuss Alnylam Pharmaceuticals Stock ↗
 
Via Benzinga
News headline image
Alnylam Announces Pricing of Upsized Offering of $575 Million Convertible Senior Notes
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam Announces Proposed Offering of $500 Million Convertible Senior Notes
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Earnings Scheduled For July 31, 2025 ↗
 
Via Benzinga
News headline image
Here's How Much $1000 Invested In Alnylam Pharmaceuticals 10 Years Ago Would Be Worth Today ↗
 
Via Benzinga
News headline image
$1000 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth This Much Today ↗
 
Via Benzinga
News headline image
Where Alnylam Pharmaceuticals Stands With Analysts ↗
 
Via Benzinga
News headline image
New Data From Landmark HELIOS-B Phase 3 Study Presented at ESC Congress 2025 Demonstrate Vutrisiran’s Long-Term Cardiovascular Benefit in ATTR-CM
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam to Advance Zilebesiran into Global Phase 3 Cardiovascular Outcomes Trial
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam to Webcast Presentations at Upcoming September Investor Conferences
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
A Closer Look at Alnylam Pharmaceuticals's Options Market Dynamics ↗
 
Via Benzinga
News headline image
How Is The Market Feeling About Alnylam Pharmaceuticals? ↗
 
Via Benzinga
News headline image
Here's How Much $100 Invested In Alnylam Pharmaceuticals 10 Years Ago Would Be Worth Today ↗
 
Via Benzinga
News headline image
Alnylam to Present Progress in Transforming the Treatment of Cardiovascular Disease with RNAi Therapeutics at European Society of Cardiology Congress 2025
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Where Alnylam Pharmaceuticals Stands With Analysts ↗
 
Via Benzinga
News headline image
Alnylam to Webcast Presentation at Canaccord Genuity 45th Annual Growth Conference
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
If You Invested $1000 In This Stock 15 Years Ago, You Would Have This Much Today ↗
 
Via Benzinga
News headline image
Demystifying Alnylam Pharmaceuticals: Insights From 19 Analyst Reviews ↗
 
Via Benzinga
News headline image
This Alnylam Pharmaceuticals Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Monday ↗
 
Via Benzinga
News headline image
Reddit, Wingstop, And Generac Are Among Top 10 Large Cap Gainers Last Week (July 28-August 1): Are The Others In Your Portfolio? ↗
Reddit, Wingstop, and Generac led large-cap gains last week on strong Q2 results and upbeat guidance across multiple sectors. 
Via Benzinga
News headline image
Alnylam's Amvuttra Makes Powerful Entrance, Eyes First-Line Dominance ↗
Alnylam sees strong Amvuttra uptake in ATTR-CM with $150 million revenue boost; analysts hike price targets following FDA approval and launch momentum. 
Via Benzinga
News headline image
Alnylam Pharmaceuticals Q2 Earnings Crush Estimates, Stock Hits 52-Week High On Upbeat Forecast ↗
Alnylam stock jumps after Q2 earnings beat and higher 2025 guidance, led by Amvuttra's rapid uptake and strong growth across the TTR and Rare franchises. 
Via Benzinga
Topics Earnings
News headline image
Roblox, Carvana, eBay, C.H. Robinson Worldwide, Huntington Ingalls Industries And Other Big Stocks Moving Higher On Thursday ↗
 
Via Benzinga
News headline image
Alnylam Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Recent Period Progress
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Here's How Much $100 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth Today ↗
 
Via Benzinga
News headline image
This Target Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday ↗
 
Via Benzinga
News headline image
This Alnylam Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗
 
Via Benzinga
News headline image
Alnylam to Webcast Conference Call Discussing Second Quarter 2025 Financial Results
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
A Glimpse Into The Expert Outlook On Alnylam Pharmaceuticals Through 10 Analysts ↗
 
Via Benzinga
News headline image
Alnylam Pharma Stock Outlook: Is ALNY Topping Out? ↗
Alnylam Pharma Stock Outlook: For new entrants, chasing the momentum at this point would offer poor risk-reward dynamics. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
20 21 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.